Tern Plc expects final results on 31 May 2023 Q&A Session to follow

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (“IoT”) technology businesses, has announced that it expects to publish its final results for the year ended 31 December 2022 on Wednesday 31 May 2023.

Investor Q&A Session

The Company’s Chairman, Ian Ritchie, and CEO, Al Sisto, will conduct a live question and answer session for investors on 12 June 2023 at 5:30 pm BST. The session is open to all existing and potential shareholders. Those who wish to attend should register via the following link where they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_YYea-W2XQgeqJ7WUDPHnuQ

Participants will have the opportunity to submit questions for Tern Plc during the session, but questions are welcomed in advance and may be submitted to: [email protected].

Share on:

You might also enjoy reading Tern notes automotive momentum at Device Authority

Written by: Jacob Brown

Find more news, interviews, share price & company profile here for:
Tern Plc

Latest Company News

Tern Plc issues 78.2m shares following Open Offer

March 3, 2026

Tern Plc announced valid acceptances for 78,163,662 Open Offer Shares at 0.40 pence per share, generating gross proceeds of about £312,654. The enlarged share capital will total 750,877,367 ordinary shares upon admission to AIM.

Fundamental XR expands access to immersive training with web-enabled platform

February 25, 2026

Its new Immersive Web platform brings immersive training into the browser, lowering adoption barriers and broadening enterprise reach.

GLP-1 receptor agonists: Strategic market shift

February 24, 2026

Rapid uptake, evolving regulation and digital integration are reshaping the investment case for metabolic health therapies.

The Cyber Resilience Act forces a security reset for connected device makers

February 17, 2026

Device Authority helps manufacturers operationalise Cyber Resilience Act compliance through automated device identity and secure update management.

Pharmaceutical groups move closer to the consumer in strategic marketing reset

February 16, 2026

Pharmaceutical marketing is shifting towards direct consumer engagement, reshaping how companies compete and manage risk in a digital environment.

Changing clinician behaviour reshapes commercial strategy for 2026

February 13, 2026

As clinician engagement becomes more digital and measurable, companies that act on behavioural data can improve targeting, reduce risk and strengthen competitive positioning in 2026.